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Ataxia telangiectasia mutated kinase plays a protective role in β-
adrenergic receptor-stimulated cardiac myocyte apoptosis and
myocardial remodeling
Cerrone R. Foster, Mahipal Singh, Venkateswaran Subramanian, and Krishna Singh
Department of Physiology, James H Quillen College of Medicine, James H Quillen Veterans




β-Adrenergic receptor (β-AR) stimulation induces cardiac myocyte apoptosis and plays an
important role in myocardial remodeling. Here we investigated expression of various apoptosis-
related genes affected by β-AR stimulation, and examined first time the role of ataxia
telangiectasia mutated kinase (ATM) in cardiac myocyte apoptosis and myocardial remodeling
following β-AR stimulation. cDNA array analysis of 96 apoptosis-related genes indicated that β-
AR stimulation increases expression of ATM in the heart. In vitro, RT-PCR confirmed increased
ATM expression in adult cardiac myocytes in response to β-AR stimulation. Analysis of left
ventricular structural and functional remodeling of the heart in wild-type (WT) and ATM
heterozygous knockout mice (hKO) 28 days after ISO-infusion showed increased heart weight to
body weight ratio in both groups. M-mode echocardiography showed increased percent fractional
shortening (%FS) and ejection fraction (EF%) in both groups 28 days post ISO-infusion.
Interestingly, the increase in %FS and EF% was significantly lower in the hKO-ISO group.
Cardiac fibrosis and myocyte apoptosis were higher in hKO mice at baseline and ISO-infusion
increased fibrosis and apoptosis to a greater extent in hKO-ISO hearts. ISO-infusion increased
phosphorylation of p53 (Serine-15) and expression of p53 and Bax to a similar extent in both
groups. hKO-Sham and hKO-ISO hearts exhibited reduced intact β1 integrin levels. MMP-2
protein levels were significantly higher, while TIMP-2 protein levels were lower in hKO-ISO
hearts. MMP-9 protein levels were increased in WT-ISO, not in hKO hearts. In conclusion, ATM
plays a protective role in cardiac remodeling in response to β-AR stimulation.
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Introduction
Ataxia telangiectasia (A–T) is an autosomal recessive disease where the ataxia telangiectasia
mutated kinase (ATM) protein is missing or inactivated. Patients suffering from A-T show a
high incidence of muscular and cerebullar degeneration, immune deficiency, lymphomas,
and insulin resistance [1–3]. Additional features in individuals with a heterozygous
phenotype include a high incidence of cancer predisposition and susceptibility to ischemic
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heart disease [4]. ATM is a multifunctional kinase regulating cellular repair following DNA
damage by activation of downstream targets [5, 6]. Among these are cell cycle regulators;
p53 and Chk2 [7]. ATM was initially thought to be localized in the nucleus, affecting only
proliferating cells [8]. Evidence has shown that ATM is present within the cytoplasm of
post-mitotic cells and plays a direct role in other disease phenotypes such as insulin
resistance and glucose intolerance [9–12]. While ATM affects multiple downstream targets
in response to cellular stress or damage, the decision to activate survival or apoptotic (cell
suicide) mechanisms may depend on the cell type and extent of damage [6].
Catecholamines, such as norepinephrine, are released during myocardial ischemia and
accumulate in the interstitial space of the heart [13, 14]. This accumulation of
catecholamines may contribute to the ischemic heart disease and heart failure [15]. Acting
via β-adrenergic receptor (β-AR), catecholamines (norepinephrine and iso-proterenol) are
shown to increase apoptosis in cardiac myocytes in vitro and in vivo, and play a role in
myocardial remodeling associated with increased cardiac fibrosis [16–21]. Cardiac myocyte
apoptosis is recognized as an important determinant of structure and function of the
myocardium [22–24]. Integrins play a crucial role in the regulation of cell growth, apoptosis
and hypertrophy [25]. Cardiac myocytes predominantly express β1 integrins [26]. Our
laboratory has provided evidence that β1 integrin signaling protects cardiac myocytes
against β-AR-stimu-lated apoptosis in vitro [27, 28] and in vivo [20]. β-AR stimulation
increases expression and activity of matrix metalloproteinase-2 (MMP-2) in cardiac
myocytes [29] and MMP-2 may interfere with the survival signals induced by β1 integrin
[28].
The increased susceptibility of A-T heterozygous patients to ischemic heart disease and the
role of ATM in myocardial remodeling following β-AR stimulation have not been
examined. Here, using cDNA array analysis of apoptosis-related genes, we identified that β-
AR stimulation increases expression of ATM. Using wild-type (WT) and ATM
heterozygous knockout mice, we report that ATM may play an important role in β-AR-
stimulated myocardial remodeling with effects on ventricular function, apoptosis and
fibrosis. To gain an insight into the mechanism by which ATM affects β-AR-stimulated
myo-cardial remodeling, we measured phosphorylation of p53, and expression of p53, Bax,
β1-integrins, MMP-2, MMP-9 and tissue inhibitors of MMPs (TIMPs). Our findings suggest
that interplay between β1 integrin and MMP-2 plays an important role in myocyte apoptosis
and myocardial remodeling during ATM deficiency.
Methods
Vertebrate animals
Heterozygous knockout (hKO) and wild-type (WT) ATM mice, purchased from the Jackson
Laboratory, were of 129x black Swiss hybrid background. Genotyping was performed by
polymerase chain reaction (PCR) using primers suggested by the Jackson Laboratory. The
absence of both ATM alleles produces a lethal phenotype at ~2 months of age mainly due to
thymic lymphomas [1, 30]. Therefore, experiments were carried out using hKO mice. The
investigation conforms to the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). The
animal protocol was approved by the University Committee on Animal Care. Mice were
euthanized by exsanguination. Animals were anesthetized using a mixture of isoflurane
(1.5%) and oxygen (0.5 l/min) and the heart was removed following a bilateral cut in the
diaphragm.
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For functional studies, L-isoproterenol (ISO; 400 µg/kg/day) was infused in age-matched (4
months old) male and female WT and hKO mice by subcutaneous implantation of mini-
osmotic pumps (Alzet) as described [20].
Cell isolation and culture
Adult rat ventricular myocytes (ARVM) were isolated as previously described [31].
RNA isolation and GEArray analysis
Total RNA was extracted from the left ventricles of sham and ISO-infused (7 days) mice
using the RNAqueous-4PCR kit (Ambion, Inc., Austin, TX) according to the manufacturer’s
instructions. Two micrograms of RNA was used as a template to generate 32P-dCTP-labeled
cDNA probes according to the manufacturer’s instructions (SuperArray Bioscience Corp.,
Frederick, MD). The cDNA probes were denatured and hybridized at 60°C with a GEArray
membrane, containing 96 apoptosis-related genes. After washing, the membrane was
incubated with a chemiluminescent substrate. The spots were digitized with ScanAlyze
software, and signal intensities were normalized to ribosomal protein L13a (Rpl13a) using
the GEarray analyzer program (SuperArray Bioscience Corp., Frederick, MD).
Cell treatment and RT-PCR
Adult rat ventricular myocytes (ARVMs), cultured for 24 h, were treated with ISO (10 µM)
in the presence of ascorbic acid (100 µM) for 24 h. Total RNA (2 µg) was reverse
transcribed using the M-MLV RT kit (Promega Corp., Madison, WI) according to the
manufacturer’s instructions. Primer sequences for RT-PCR amplification were as follows:
ATM; 5′-GATCTGTGGGTGTTCCGACT-3′ and 5′-CTTTGGGTGCATTCTTGGTT-3′,
GAPDH; 5′-CTC ATGACCACAGTCCATGC-3′ and 5′-TTCAGCTCTGGG
ATGACCTT-3′. PCR products were analyzed by gel electrophoresis on a 2% agarose gel
stained with ethidium bromide.
Echocardiography
Transthoracic two-dimensional M-mode echocardiography was performed using a Toshiba
Aplio 80 Imaging System (Tochigi, Japan) equipped with a 12 MHz linear transducer. Mice
were anesthetized using a mixture of isoflurane (1.5%) and oxygen (0.5 l/min). The body
temperature was maintained at ~ 37°C using a heating pad. Measurements were averaged
from nine different readings per mouse [20, 32]. Percent fractional shortening (%FS) and
ejection fractions (EF%) were calculated [20]. All echocardiographic assessments and
measurements were performed by the same investigator. A second person also performed
measurements on a separate occasion using the same recordings with no significant
differences in interobserver variability.
Morphometric analyses
Following ISO-infusion, animals were killed and hearts were arrested in diastole using KCl
(30 mmol/l) followed by perfusion fixation with 10% buffered formalin. Cross sections (4
µm thick) were stained with Masson’s trichrome for the measurement of fibrosis using
Bioquant image analysis software (Nashville, TN).
Apoptosis
To detect apoptosis, TUNEL staining was carried out on 4-µm thick sections as per
manufacturer’s instructions (cell death detection assay kit, Roche). To identify apoptosis
associated with cardiac myocytes, the sections were immunostained using α-sarcomeric
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actin antibodies (1:50; 5C5 clone, Sigma). Hoechst 33258 staining was used to determine
the total number of nuclei. Apoptosis was calculated as the percentage of apoptotic cardiac
myocyte nuclei/total number of nuclei.
Western blot analysis
LV lysates were prepared in RIPA buffer as previously described [20]. Protein lysates (75
µg) were separated by SDS-PAGE (10%) and transferred to a PVDF membrane (240 mA,
2.5 h). The membranes were incubated with antibodies against p53, p-p53 (serine-15; Cell
Signaling), Bax (Santa Cruz), β1 integrin (Transduction Lab.), MMP-9 and MMP-2
(Millipore), TIMP-2 and TIMP-4 (Chemicon). The immune complexes were detected using
chemilumi-nescence reagents (Pierce Biotech.). Membranes were stripped and probed with
GAPDH (Santa Cruz) as a protein loading control. Band intensities were quantified using
Kodak photodocumentation system (Eastman Kodak Co.).
Statistical analyses
Data are represented as mean ± SEM. Data were analyzed using student’s t test or one-way
analysis of variance (ANOVA) and a post hoc Tukey’s test. Probability values of <0.05
were considered to be significant.
Results
β-AR stimulation increases ATM expression
GEArray analysis of apoptosis-related genes indicated that β-AR stimulation modulates
expression of apoptosis-related genes, specifically increasing expression of ATM and
BNIP-3. This analysis showed decreased expression of Bcl2 following β-AR stimulation
(Fig. 1a, b). RT-PCR analyses of total RNA indicated ~2.5 fold increase in ATM mRNA
following β-AR stimulation (Fig. 1c). Involvement of BNIP-3 in cardiac myocyte apoptosis
and myocardial remodeling has previously been examined [33–36]. However, the role of
ATM in cardiac myocyte apoptosis and myocardial remodeling has not been previously
investigated. Therefore, we investigated the role of ATM in β-AR-stimulated cardiac
myocyte apoptosis and myocardial remodeling.
Morphometric studies
There was no significant difference in the body weights before or 28 days after ISO-infusion
between WT and hKO groups. Heart weight (HW) and HW to body weight (BW) ratios
were increased in both ISO-infused groups (P < 0.05; Table 1) with no significant difference
between the two ISO groups.
Echocardiographic studies
No differences in the echocardiographic parameters were observed between baseline (n = 8–
9) and sham (n = 4) groups at any time-point. Therefore, they were grouped as sham to
obtain a larger sample size. There was no difference in %FS and EF% between the two sham
groups. Percent FS and EF% were increased in both ISO groups when compared to the
respective sham groups. However, the increase in %FS and EF% was significantly lower in
the hKO-ISO group when compared to WT-ISO (*P<0.05 versus WT-sham and hKO-
sham; #P<0.005 versus WT-ISO; Fig. 2). There was no difference in posterior and septal
wall thicknesses between the genotypes following ISO-infusion (data not shown).
Fibrosis and apoptosis
Quantitative analysis of fibrosis using trichrome-stained sections revealed increased fibrosis
in hKO-sham mice versus WT-sham ($P < 0.01 versus WT-sham). ISO-infusion
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significantly increased the amount of fibrosis in both groups. However, the increase in
fibrosis was greater in hKO-ISO group when compared to WT-ISO (*P < 0.001 versus WT-
sham and hKO-sham; #P < 0.01 versus WT-ISO; Fig. 3a).
TUNEL-staining assay revealed increased cardiac myo-cyte apoptosis in the hKO-sham
versus WT-sham group ($P < 0.05 versus WT-sham). ISO-infusion increased the number of
apoptotic cardiac myocytes in both groups. However, the increase in apoptotic cardiac
myocytes was significantly higher in the hKO-ISO group when compared to WT-ISO (*P <
0.01 versus WT-sham and hKO-sham; #P < 0.05 versus WT-ISO; Fig. 3b).
Phosphorylation of p53 and expression of p53 and Bax
The tumor suppressor protein p53 is phosphorylated by a number of protein kinases in
response to stress stimuli. Following DNA damage, ATM phosphorylates p53 on serine-15
resulting in activation of downstream apoptotic signaling pathways [37, 38]. We therefore
examined expression and phosphorylation of p53 in response to β-AR stimulation in WT
and hKO hearts. Western blot analysis of LV lysates using anti-p53 antibodies showed no
immunostaining for p53 in WT-sham or hKO-sham groups. ISO-infusion increased levels of
p53 protein with no significant difference between the two ISO groups (Fig. 4a). Likewise,
ISO-infusion increased phosphorylation of p53 (serine-15) to a similar extent in both groups
(Fig. 4a). p53 is shown to transcriptionally increase expression of a pro-apoptotic protein,
Bax [39]. Western blot analysis of LV lysates using anti-Bax antibodies showed that ISO-
infusion increases Bax expression to a similar extent in WT and hKO hearts (Fig. 4b).
Expression of β1 integrin, MMPs, and TIMPs
Recently, our laboratory has shown that stimulation of β1 integrin signaling protects cardiac
myocytes against β-AR-stimulated apoptosis in vitro and in vivo [20, 28, 40]. Western blot
analysis of LV lysates using anti-β1 integrin antibodies showed a significant reduction in the
levels of intact β1 integrin protein in hKO-sham versus WT-sham (Fig. 5a). ISO-infusion
had no effect on the levels of intact β1 integrin and β1 integrin levels remained lower in
hKO-ISO versus WT-ISO hearts. Interestingly, appearance of a β1 integrin immunoreactive
band with an apparent molecular weight of ~55 kDa was observed in both ISO-infused
groups. The intensity of this ~55 kDa fragment was significantly higher in hKO-ISO group
($P < 0.05 versus WT-sham; #P < 0.05 versus WT-ISO, n = 4 Fig. 5). Monoclonal
antibodies raised against the extracellular domain of β1 integrin were used for western blot
analysis. Therefore, the ~55 kDa band most likely represents the previously identified
extracellular domain of β1 integrin [41].
Activation of MMP-2 may play a role in the fragmentation of β1 integrin [29]. Therefore,
we next analyzed expression of MMP-2 and MMP-9 by western blot. ISO-infusion
increased MMP-2 protein levels in both groups. However, the increase in MMP-2 protein
was significantly higher in the hKO-ISO group (Fig. 6a). MMP-9 protein levels were
increased only in the WT-ISO, not in hKO-ISO group (Fig. 6a).
TIMP-2 is suggested to inhibit MMP-2 activity [42], while TIMP-4 is predominantly
expressed in the heart [43]. Western blot analysis showed increased TIMP-2 protein levels
in hKO-sham when compared to WT-sham. ISO-infusion decreased TIMP-2 protein levels
in the hKO, but not in the WT group (Fig. 6b). ISO-infusion and/or ATM deficiency had no
effect on TIMP-4 protein levels (Fig. 6b).
Discussion
Ataxia telangiectasia mutated kinase (ATM) has been linked to various signaling pathways
regulating multiple diseases which include diabetes [9, 44] and metabolic syndrome with
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effects on atherosclerosis [45]. This is the first study to suggest that β-AR stimulation
increases expression of ATM, and ATM plays a crucial role in β-AR-stimulated myocardial
remodeling with effects on cardiac myocyte apoptosis and left ventricular fibrosis and
function. ATM deficiency induces remodeling of the heart at basal levels with increased
myocyte apoptosis and myo-cardial fibrosis. β-AR stimulation induced cardiac hypertrophy
and increased %FS and EF% in both groups. However, the increase in %FS and EF% was
lower in ATM deficient mice. β-AR stimulation increased cardiac myo-cyte apoptosis and
fibrosis in both WT and ATM deficient mice. However, the increase in fibrosis and
apoptosis was higher in ATM deficient mice. ATM deficiency had no effect on β-AR-
stimulated increases in the expression and phosphorylation of apoptosis-related proteins (p-
p53, p53, and Bax), while it negatively affected expression of β1 integrin and other
extracellular matrix proteins.
In cells of non-cardiac origin, expression of ATM is shown to be regulated by radiation and
growth factors [46, 47]. The ATM promoter has a number of potentially important cis-
regulatory sequences, including a modified AP-1 site fat specific element (Fse) [48]. The
Fse site is shown to bind Fos-Jun complexes, making it an alternate binding site for the AP-1
transcription factor [49]. The transcription factor AP-1 is formed by dimerization of
different members of Fos and Jun protein family members. The expression of Fos and Jun is
mainly regulated via the activation of ERK1/2 and JNKs, respectively. Here, we show for
the first time that adult cardiac myocytes express ATM at basal levels. Stimulation of β-AR
increases expression of ATM in vivo and in vitro. Previously, β-AR stimulation is shown to
activate ERK1/2 and JNKs [31]. Therefore, it is likely that β-AR stimulation increases
expression of ATM via the involvement of ERK1/2 and JNKs.
Ventricular hypertrophy is an important compensatory mechanism that allows the heart to
maintain its output. HW/ BW ratio, a measure of hypertrophy was increased to a similar
extent in both groups in response to β-AR stimulation. However, results from M-mode
echocardiography revealed a decrease in %FS and EF% in ATM deficient mice in response
to β-AR stimulation, suggesting compromised myocardial performance of these mice after
chronic ISO stimulation. Cardiac myocyte loss due to apoptosis plays an important role in
the pathogenesis of the heart [22–24]. Stimulation of β-AR increases apoptosis in cardiac
myocytes in vitro and in vivo, and myocardial remodeling associated with increased cardiac
fibrosis [16–19, 50]. Increased fibrosis is suggested to poorly affect myocardial performance
by decreasing the elastic recoil of the heart [51]. ATM deficiency resulted in increased
cardiac myocyte apoptosis at basal levels and 28 days after ISO-infusion. Basal fibrosis was
higher in ATM deficient mice, and was exaggerated following chronic β-AR stimulation.
Since changes in cardiac function are not an isolated event, it is possible that the greater
amounts of myocardial fibrosis and cardiac myocyte apoptosis in ATM deficient mice (Fig.
3a, b) may account for the observed %FS and EF% in these mice after chronic β-AR
stimulation.
The p53 tumor suppressor gene plays a key role in cell death through transcriptional
regulation of downstream apoptotic targets [37, 52]. In response to DNA damage, ATM
phosphorylates p53 on serine-15 resulting in stabilization of p53 [53]. Stabilization of p53
may increase the transcriptional activity of p53, ultimately leading to apoptosis [54].
Consistent with these observations, we observed increased protein levels of p53 and its
phosphorylation in response ISO in the WT group with no effect in ATM deficient hearts.
Downstream effects of p53 include activation of pro-apoptotic factors such as the
mitochondrial protein Bax [39]. β-AR stimulation increased Bax expression in WT and hKO
hearts to a similar extent. It is possible that one copy of the ATM gene is sufficient to
activate p53-dependent apoptotic signaling in response to β-AR stimulation.
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Previously our laboratory has provided evidence that β1 integrins play a protective role in β-
AR-stimulated apop-tosis (in vitro and in vivo), and MMP-2 interferes with the β1 integrin-
mediated survival signals [20, 28, 55]. Evidence has also been provided that purified
TIMP-2 inhibits β-AR-stimulated apoptosis in cardiac myocytes [29]. TIMP-2 is suggested
to inhibit MMP-2 activity [42]. The data presented here show decreased β1 integrin levels in
ATM deficient hearts at basal levels. The levels of intact β1 integrin remained lower in
ATM deficient hearts in response to ISO-infusion. Interestingly, the levels of a 55 kDa
protein, a likely extracellular fragment of β1 integrin, were greatly increased in ATM
deficient hearts. ATM deficient hearts also exhibited increased MMP-2 expression and
decreased TIMP-2 expression. Taken together, these observations suggest (1) decreased β1
integrin expression in ATM deficient hearts; and (2) shedding of the extracellular domain of
β1 integrin, possibly via the activation of MMP-2. Decreased β1 integrin expression and/or
shedding of β1 integrins may ultimately affect the anti-apoptotic signaling pathway induced
by β1 integrin during β-AR stimulation in ATM deficient hearts. ATM may regulate
expression of MMP-2 and β1 integrin via the modulation of activities of transcription factors
such as AP-1 and NF-kB [56]. A functional AP-1 binding site in the promoter region of
MMP-2 has been identified in rat cardiac cells [57]. In cardiac fibroblasts, activation of NF-
κB plays an important role in the regulation of MMP-2 and MMP-9 expression and activity
[58]. Activation of AP-1 and NF-κB may also modulate β1 integrin expression [59].
However, further studies are needed to examine the role of ATM in the regulation of
MMP-2 and β1 integrin expression.
Cardiac fibrosis is promoted by extracellular matrix remodeling (ECM) and is a common
and well recognized feature of heart failure (HF) [60]. MMP-9 and MMP-2 are suggested to
play a major role in ECM remodeling by continued degradation of collagen leading to left
ventricular dilation and pump dysfunction [61]. Here we observed no change in MMP-9
expression but an increase in MMP-2 expression following chronic ISO-infusion in hKO
mice. The up regulation of MMP-2 in the hKO group correlates with increased amounts of
fibrosis. Several reports have shown increased MMP-2 expression with myocardial
remodeling and that inhibition of MMP’s is shown to attenuate LV remodeling in several
HF models [62–64]. Doxycyline, MMP inhibitor, is shown to attenuate ISO-induced
myocardial fibrosis and MMP activity in rats [65]. Also expression of active MMP-2
induced severe ventricular remodeling with replacement fibrosis and systolic dysfunction
with increased left ventricular volumes in the absence of injury [66]. Replacement fibrosis
(formation of scar tissue) follows an inflammatory cell response that appears at the sites of
cardiac myocyte necrosis preserves the structural integrity of the myocardium [67]. This
replacement fibrosis is distinct from reactive fibrosis that surrounds intramyocardial
coronary arteries and may extend into the contiguous interstitial space with time. Reactive
fibrosis has been observed in hypertensive animal models [68]. Apoptosis usually does not
associate with inflammatory response. Therefore, increased myfocardial fibrosis observed at
basal levels in ATM deficient mice and following ISO-infusion (in WT and hKO mice) may
be due to reactive fibrosis. However, the involvement of necrosis and/or apoptosis in this
process cannot be ruled out.
Ataxia telangiectasia mutated kinase (ATM) is a key regulator of multiple signaling
pathways in response to DNA damage. The data presented here suggest that ATM has the
potential to play a crucial role in β-AR-stimulated left ventricular dysfunction with effects
on cardiac myo-cyte apoptosis and fibrosis. It is interesting to note that deficiency of ATM
associates with decreased cardiac function and increased cardiac myocyte apoptosis. The
data presented here suggest that reduced levels of intact β1 integrins with increased MMP-2
may enhance cardiac myocyte apoptosis and myocardial dysfunction during ATM
deficiency. Investigation of signaling pathways that can shift the balance from cell survival
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to apoptosis during chronic β-adrenergic stimulation may have important clinical
implications.
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β-AR stimulation increases ATM expression. a Autoradiograms representing expression of
apoptosis-related genes in sham and ISO-infused hearts. b Quantitative analysis of ATM,
Bcl-2, and BNIP3 expression 7 days after ISO-infusion. The data normalized using
ribosomal protein L13a (Rpl13a) gene expression as a control. c RT-PCR analyses. Total
RNAs were reverse transcribed and resulting cDNAs were subjected to amplification of
ATM and GAPDH genes. The upper panel depicts a 2% agarose gel of the RT-PCR. The
lower panel exhibits the mean data from sham and ISO-treated animals normalized to
GAPDH (n = 3, *P < 0.05)
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LV remodeling in ATM deficient mice following ISO-infusion. Echocardographic M-Mode
measurements of WT and hKO mice 28 days following ISO-infusion. a Percent fractional
shortening, %FS. b Ejection fraction, EF. Values are show as mean ± SE; (sham, n = 12–13;
ISO, n = 11; *P < 0.05 versus WT-sham and hKO-sham, #P < 0.005 versus WT-ISO)
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Myocardial Remodeling. a. Masson’s trichrome-stained sections demonstrating fibrosis in
WT and hKO mice 28 days after ISO-infusion. b Quantitative analysis of fibrosis 28 days
after ISO-infusion. $P < 0.01 versus WT-sham, n = 3–4; *P < 0.001 versus WT-sham and
hKO-sham; #P < 0.01 versus WT-ISO; n = 6–7. c Quantitative analysis of TUNEL-stained
myocytes 28 days after ISO-infusion. $P < 0.05 versus WT-sham; *P < 0.01 versus WT-
sham and hKO-sham, n = 3–4; #P < 0.05 versus WT-ISO; n = 6–7
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Expression of apoptosis related proteins 28 days after ISO-infusion. a Expression and
phosphorylation of p53. b Expression of Bax. Total LV lysates (50 µg) were analyzed by
western blot using anti-p53 and phospho-specific (serine-15) p53 antibodies or anti-Bax
antibodies (*P < 0.05 versus respective shams). Protein loading in each lane is indicated by
GAPDH immunostaining. The lower panels exhibit mean data normalized to GAPDH (n =
4)
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Expression of β1 integrin 28 days after ISO-infusion. Total LV lysates were analyzed by
western blot using anti-β1 integrin antibodies. Autoradiograms indicating the intact 130 kDa
β1 integrin and the 55 kDa β1 integrin (cytoplasmic) fragment. Protein loading in each lane
is indicated by GAPDH immunostaining. The middle panel shows quantitative analysis of
intact β1 integrin ($P < 0.05 versus WT-sham; #P < 0.05 versus WT-ISO, n = 4) normalized
to GAPDH. The lower panel shows quantitative analysis of β1 integrin fragment (#P < 0.005
versus WT-ISO; n = 4) normalized to GAPDH and shown as fold increase versus WT-ISO
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Expression of MMPs and TIMPs 28 days after ISO-infusion. a MMP-2 and MMP-9
expression. Total LV lysates were analyzed by western blot using anti-MMP-2 or anti-
MMP-9 antibodies. The upper panel shows autoradiograms indicating immunostaining for
MMP-2, MMP-9, and GAPDH. The lower panel shows quantitative analysis of MMP-2 (*P
< 0.05 versus WT-Sham and hKO-sham; #P < 0.01 versus WT-ISO; n = 4) and MMP-9 (*P
< 0.05 versus WT-Sham and hKO-sham; #P < 0.01 versus WT-ISO; n = 4) normalized to
GAPDH. b TIMP-2 and TIMP-4 expression. Total LV lysates were analyzed by western
blot using anti-TIMP-2 and TIMP-4 antibodies. The upper panel shows autoradiograms
indicating immunostaining for TIMP-2, TIMP-4, and GAPDH. The lower panel shows
quantitative analysis of TIMP-2 (*P < 0.05 versus hKO-sham; $P < 0.05 versus WT-sham; n
= 4) and TIMP-4 protein levels (P = NS) normalized to GAPDH
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